J Van den Brande
Overview
Explore the profile of J Van den Brande including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, et al.
Sarcoma
. 2016 Nov;
2016:7461783.
PMID: 27843394
. Preclinical data indicate that trabectedin followed by irinotecan has strong synergistic effects on Ewing sarcoma. This is presumably due to hypersensitization of the tumor cells to the camptothecin as...
2.
Franssens V, Bynens T, Van den Brande J, Vandermeeren K, Verduyckt M, Winderickx J
Oxid Med Cell Longev
. 2013 Aug;
2013:760629.
PMID: 23936613
Over the past decade, the baker's yeast Saccharomyces cerevisiae has proven to be a useful model system to investigate fundamental questions concerning the pathogenic role of human proteins in neurodegenerative...
3.
Calvo E, Vermorken J, Hiret S, Rodon J, Cortes J, Senellart H, et al.
Cancer Chemother Pharmacol
. 2012 Mar;
69(6):1467-75.
PMID: 22382883
Background: Vinflunine is a new microtubule inhibitor of the vinca-alkaloid family. It is marketed in transitional cell carcinoma of urothelial tract as a 20 min infusion given every 3 weeks...
4.
Peeters M, Van den Brande J, Francque S
Acta Gastroenterol Belg
. 2010 May;
73(1):25-36.
PMID: 20458847
This paper reviews the research that has been conducted into the use of Sandostatin to control the debilitating symptoms of diarrhea in a number of different etiologies. These are cancer-related...
5.
Spoormans I, Altintas S, Van den Brande J, Luijks A, Vermorken J
Ann Oncol
. 2008 Apr;
19(6):1204-7.
PMID: 18407952
No abstract available.
6.
Kohne C, De Greve J, Hartmann J, Lang I, Vergauwe P, Becker K, et al.
Ann Oncol
. 2007 Dec;
19(5):920-6.
PMID: 18065406
Background: The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the...
7.
Specenier P, Van den Weyngaert D, Van Laer C, Weyler J, Van den Brande J, Huizing M, et al.
Ann Oncol
. 2007 Sep;
18(11):1856-60.
PMID: 17823386
Background: Radiotherapy (RT) with concurrent chemotherapy is the current standard of care for patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN). Gemcitabine (GEM) is...
8.
Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, et al.
Br J Cancer
. 2007 May;
96(11):1692-8.
PMID: 17486132
The aim of the study was to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and the pharmacokinetic profile (Pk) of bendamustine (BM) on a day 1...
9.
Altintas S, Blockx N, Huizing M, Van den Brande J, Hoekx L, Bogers J, et al.
Ann Oncol
. 2006 Dec;
18(4):801-4.
PMID: 17182974
No abstract available.
10.
Colebunders R, Bottieau E, Van den Brande J, Colpaert C, Marck E
HIV Med
. 2004 Nov;
5(6):452-4.
PMID: 15544700
A 25-year-old HIV-infected African albino woman developed an aggressive Merkel cell carcinoma on her face and at least 10 basal cell carcinomas, mainly on sun-exposed parts of her body. HIV...